デフォルト表紙
市場調査レポート
商品コード
1609653

日本のがんバイオマーカー市場レポート:プロファイリング技術、生体分子、がんタイプ、用途、エンドユーザー、地域別、2025年~2033年

Japan Cancer Biomarkers Market Report by Profiling Technology, Biomolecule, Cancer Type, Application, End User, and Region 2025-2033


出版日
発行
IMARC
ページ情報
英文 119 Pages
納期
5~7営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.30円
日本のがんバイオマーカー市場レポート:プロファイリング技術、生体分子、がんタイプ、用途、エンドユーザー、地域別、2025年~2033年
出版日: 2024年12月05日
発行: IMARC
ページ情報: 英文 119 Pages
納期: 5~7営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

日本のがんバイオマーカー市場の市場規模は2024年に12億5,260万米ドルに達しました。今後、IMARC Groupは、市場は2033年までに36億2,130万米ドルに達し、2025年から2033年にかけて11.2%の成長率(CAGR)を示すと予測しています。がん患者の増加と、治療を成功させ患者の予後を改善するための効果的な診断・モニタリングツールに対するニーズの高まりが、市場を牽引しています。

本レポートで扱う主な質問

  • 日本のがんバイオマーカー市場はこれまでどのように推移し、今後どのように推移していくのか?
  • COVID-19の日本のがんバイオマーカー市場への影響は?
  • 日本のがんバイオマーカー市場のプロファイリング技術別の内訳は?
  • 日本のがんバイオマーカー市場の生体分子別の内訳は?
  • 日本のがんバイオマーカー市場のがんタイプ別の内訳は?
  • 日本のがんバイオマーカー市場の用途別の内訳は?
  • 日本のがんバイオマーカー市場のエンドユーザー別の内訳は?
  • 日本のがんバイオマーカー市場のバリューチェーンにはどのような段階がありますか?
  • 日本のがんバイオマーカーの主な促進要因と課題は何か?
  • 日本のがんバイオマーカー市場の構造と主要プレーヤーは?
  • 日本のがんバイオマーカー市場における競合の程度は?

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
  • 市場推定
  • 調査手法

第3章 エグゼクティブサマリー

第4章 日本のがんバイオマーカー市場:イントロダクション

  • 概要
  • 市場力学
  • 業界動向
  • 競合情報

第5章 日本のがんバイオマーカー市場情勢

  • 過去および現在の市場動向(2019年~2024年)
  • 市場予測(2025-2033)

第6章 日本のがんバイオマーカー市場:プロファイリング技術別の内訳

  • オミックテクノロジーズ
  • イメージング技術
  • 免疫測定
  • 細胞遺伝学

第7章 日本のがんバイオマーカー市場:生体分子別の内訳

  • 遺伝子バイオマーカー
  • タンパク質バイオマーカー
  • 糖質バイオマーカー

第8章 日本のがんバイオマーカー市場:蟹座タイプ別の内訳

  • 乳がん
  • 肺がん
  • 大腸がん
  • 前立腺がん
  • 胃がん
  • その他

第9章 日本のがんバイオマーカー市場:用途別の内訳

  • 診断
  • 予測
  • リスクアセスメント
  • 医薬品の発見と開発
  • その他

第10章 日本のがんバイオマーカー市場:エンドユーザー別の内訳

  • 病院
  • 学術研究機関
  • 外来手術センター
  • 診断検査室
  • その他

第11章 日本のがんバイオマーカー市場:競合情勢

  • 概要
  • 市場構造
  • 市場プレーヤーのポジショニング
  • 主要成功戦略
  • 競合ダッシュボード
  • 企業評価象限

第12章 主要企業のプロファイル

第13章 日本のがんバイオマーカー市場:業界分析

  • 促進要因・抑制要因・機会
  • ポーターのファイブフォース分析
  • バリューチェーン分析

第14章 付録

目次
Product Code: SR112024A18702

Japan cancer biomarkers market size reached USD 1,252.6 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 3,621.3 Million by 2033, exhibiting a growth rate (CAGR) of 11.2% during 2025-2033. The increasing cases of cancer, coupled with the rising need for effective diagnostic and monitoring tools to significantly improve the chances of successful treatment and better patient outcomes, are driving the market.

Cancer biomarkers are molecules or substances found in the body that can indicate the presence of cancer or provide information about its characteristics. These biomarkers are typically detected through blood tests, tissue samples, or imaging studies. They play a crucial role in cancer diagnosis, prognosis, and treatment. Biomarkers can include proteins, genes, hormones, or even specific cellular changes. By analyzing their levels or activity, healthcare professionals can identify the type of cancer, its stage, and its potential aggressiveness. This information helps in tailoring treatment plans, monitoring disease progression, and assessing treatment effectiveness. Cancer biomarkers also have a significant impact on personalized medicine, enabling doctors to choose the most appropriate therapies for individual patients. Additionally, they aid in cancer research, facilitating the development of new drugs and therapies. Overall, cancer biomarkers are essential tools in the fight against cancer, contributing to early detection, precise treatment, and improved patient outcomes.

Japan Cancer Biomarkers Market Trends:

The cancer biomarkers market in Japan is driven by several key factors that collectively contribute to its growth and significance in the field of oncology. Firstly, advancements in molecular biology and genomics have paved the way for the identification of novel biomarkers that can aid in early cancer detection and prognosis. Moreover, the increasing prevalence of cancer in Japan is a major driver, as there is a growing need for accurate and efficient diagnostic tools to combat this regional health challenge. Furthermore, the development of targeted therapies and personalized medicine approaches has accentuated the demand for biomarkers. These biomarkers assist in tailoring treatment plans to individual patients, improving the overall efficacy of cancer treatments while minimizing adverse effects. Additionally, the rise in R&D activities in the pharmaceutical and biotechnology sectors has spurred investments in biomarker discovery and validation, further propelling market growth. Moreover, the widespread adoption of liquid biopsy techniques for non-invasive biomarker detection, as they offer a less invasive alternative to traditional tissue biopsies, is expected to drive the cancer biomarkers market in Japan during the forecast period.

Japan Cancer Biomarkers Market Segmentation:

Profiling Technology Insights:

  • Omic Technologies
  • Imaging Technologies
  • Immunoassays
  • Cytogenetics

Biomolecule Insights:

  • Genetic Biomarkers
  • Protein Biomarkers
  • Glyco-Biomarkers

Cancer Type Insights:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Stomach Cancer
  • Others

Application Insights:

  • Diagnostics
  • Prognostics
  • Risk Assessment
  • Drug Discovery and Development
  • Others

End User Insights:

  • Hospitals
  • Academic and Research Institutions
  • Ambulatory Surgical Centers
  • Diagnostic Laboratories
  • Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan cancer biomarkers market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan cancer biomarkers market?
  • What is the breakup of the Japan cancer biomarkers market on the basis of profiling technology?
  • What is the breakup of the Japan cancer biomarkers market on the basis of biomolecule?
  • What is the breakup of the Japan cancer biomarkers market on the basis of cancer type?
  • What is the breakup of the Japan cancer biomarkers market on the basis of application?
  • What is the breakup of the Japan cancer biomarkers market on the basis of end user?
  • What are the various stages in the value chain of the Japan cancer biomarkers market?
  • What are the key driving factors and challenges in the Japan cancer biomarkers?
  • What is the structure of the Japan cancer biomarkers market and who are the key players?
  • What is the degree of competition in the Japan cancer biomarkers market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Cancer Biomarkers Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Cancer Biomarkers Market Landscape

  • 5.1 Historical and Current Market Trends (2019-2024)
  • 5.2 Market Forecast (2025-2033)

6 Japan Cancer Biomarkers Market - Breakup by Profiling Technology

  • 6.1 Omic Technologies
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2019-2024)
    • 6.1.3 Market Forecast (2025-2033)
  • 6.2 Imaging Technologies
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2019-2024)
    • 6.2.3 Market Forecast (2025-2033)
  • 6.3 Immunoassays
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2019-2024)
    • 6.3.3 Market Forecast (2025-2033)
  • 6.4 Cytogenetics
    • 6.4.1 Overview
    • 6.4.2 Historical and Current Market Trends (2019-2024)
    • 6.4.3 Market Forecast (2025-2033)

7 Japan Cancer Biomarkers Market - Breakup by Biomolecule

  • 7.1 Genetic Biomarkers
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2019-2024)
    • 7.1.3 Market Forecast (2025-2033)
  • 7.2 Protein Biomarkers
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2019-2024)
    • 7.2.3 Market Forecast (2025-2033)
  • 7.3 Glyco-Biomarkers
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2019-2024)
    • 7.3.3 Market Forecast (2025-2033)

8 Japan Cancer Biomarkers Market - Breakup by Cancer Type

  • 8.1 Breast Cancer
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2019-2024)
    • 8.1.3 Market Forecast (2025-2033)
  • 8.2 Lung Cancer
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2019-2024)
    • 8.2.3 Market Forecast (2025-2033)
  • 8.3 Colorectal Cancer
    • 8.3.1 Overview
    • 8.3.2 Historical and Current Market Trends (2019-2024)
    • 8.3.3 Market Forecast (2025-2033)
  • 8.4 Prostate Cancer
    • 8.4.1 Overview
    • 8.4.2 Historical and Current Market Trends (2019-2024)
    • 8.4.3 Market Forecast (2025-2033)
  • 8.5 Stomach Cancer
    • 8.5.1 Overview
    • 8.5.2 Historical and Current Market Trends (2019-2024)
    • 8.5.3 Market Forecast (2025-2033)
  • 8.6 Others
    • 8.6.1 Historical and Current Market Trends (2019-2024)
    • 8.6.2 Market Forecast (2025-2033)

9 Japan Cancer Biomarkers Market - Breakup by Application

  • 9.1 Diagnostics
    • 9.1.1 Overview
    • 9.1.2 Historical and Current Market Trends (2019-2024)
    • 9.1.3 Market Forecast (2025-2033)
  • 9.2 Prognostics
    • 9.2.1 Overview
    • 9.2.2 Historical and Current Market Trends (2019-2024)
    • 9.2.3 Market Forecast (2025-2033)
  • 9.3 Risk Assessment
    • 9.3.1 Overview
    • 9.3.2 Historical and Current Market Trends (2019-2024)
    • 9.3.3 Market Forecast (2025-2033)
  • 9.4 Drug Discovery and Development
    • 9.4.1 Overview
    • 9.4.2 Historical and Current Market Trends (2019-2024)
    • 9.4.3 Market Forecast (2025-2033)
  • 9.5 Others
    • 9.5.1 Historical and Current Market Trends (2019-2024)
    • 9.5.2 Market Forecast (2025-2033)

10 Japan Cancer Biomarkers Market - Breakup by End User

  • 10.1 Hospitals
    • 10.1.1 Overview
    • 10.1.2 Historical and Current Market Trends (2019-2024)
    • 10.1.3 Market Forecast (2025-2033)
  • 10.2 Academic and Research Institutions
    • 10.2.1 Overview
    • 10.2.2 Historical and Current Market Trends (2019-2024)
    • 10.2.3 Market Forecast (2025-2033)
  • 10.3 Ambulatory Surgical Centers
    • 10.3.1 Overview
    • 10.3.2 Historical and Current Market Trends (2019-2024)
    • 10.3.3 Market Forecast (2025-2033)
  • 10.4 Diagnostic Laboratories
    • 10.4.1 Overview
    • 10.4.2 Historical and Current Market Trends (2019-2024)
    • 10.4.3 Market Forecast (2025-2033)
  • 10.5 Others
    • 10.5.1 Historical and Current Market Trends (2019-2024)
    • 10.5.2 Market Forecast (2025-2033)

11 Japan Cancer Biomarkers Market - Competitive Landscape

  • 11.1 Overview
  • 11.2 Market Structure
  • 11.3 Market Player Positioning
  • 11.4 Top Winning Strategies
  • 11.5 Competitive Dashboard
  • 11.6 Company Evaluation Quadrant

12 Profiles of Key Players

  • 12.1 Company A
    • 12.1.1 Business Overview
    • 12.1.2 Product Portfolio
    • 12.1.3 Business Strategies
    • 12.1.4 SWOT Analysis
    • 12.1.5 Major News and Events
  • 12.2 Company B
    • 12.2.1 Business Overview
    • 12.2.2 Product Portfolio
    • 12.2.3 Business Strategies
    • 12.2.4 SWOT Analysis
    • 12.2.5 Major News and Events
  • 12.3 Company C
    • 12.3.1 Business Overview
    • 12.3.2 Product Portfolio
    • 12.3.3 Business Strategies
    • 12.3.4 SWOT Analysis
    • 12.3.5 Major News and Events
  • 12.4 Company D
    • 12.4.1 Business Overview
    • 12.4.2 Product Portfolio
    • 12.4.3 Business Strategies
    • 12.4.4 SWOT Analysis
    • 12.4.5 Major News and Events
  • 12.5 Company E
    • 12.5.1 Business Overview
    • 12.5.2 Product Portfolio
    • 12.5.3 Business Strategies
    • 12.5.4 SWOT Analysis
    • 12.5.5 Major News and Events

13 Japan Cancer Biomarkers Market - Industry Analysis

  • 13.1 Drivers, Restraints, and Opportunities
    • 13.1.1 Overview
    • 13.1.2 Drivers
    • 13.1.3 Restraints
    • 13.1.4 Opportunities
  • 13.2 Porters Five Forces Analysis
    • 13.2.1 Overview
    • 13.2.2 Bargaining Power of Buyers
    • 13.2.3 Bargaining Power of Suppliers
    • 13.2.4 Degree of Competition
    • 13.2.5 Threat of New Entrants
    • 13.2.6 Threat of Substitutes
  • 13.3 Value Chain Analysis

14 Appendix